BCRXBioCryst Pharmaceuticals, Inc.

$8.56+11% 1Y

$8.56

$6.2452 weeks$10.59

Latest close: back above its 200-day averageOct 9, 2026what changed →

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +69% year on year, but operating margin narrowing (−89.2 points).

1 good, 1 to watch, 1 without data

Revenue trend+69% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +64% a year.

Margin direction−89.2 points operating

Trailing-twelve-month operating margin, -80.2% now against 9.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 2% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is BCRX growing?

BioCryst Pharmaceuticals, Inc. has grown revenue 45% a year over three years and 64% a year over five.

+45%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +64%
Revenue growth, 5-year rate · +45% over three · growth has slowed since the five-year average
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Details›